


Claims:

1. A compound of Formula (I):



(I)

or a pharmaceutically acceptable salt thereof, wherein:

A and G are independently CR⁵ or N;

D and E are independently CH or N;

R¹ is H;

R² is H;

or R¹ and R² together with the carbon to which they are attached form carbonyl;

R³ is H or OMe;

R⁴ is H or OMe;

R⁵ is independently selected from H, F, Cl, CN, Me or OMe;

R⁶ is H, Me or F;

R⁷ is H, Me or F;

or R⁶ and R⁷ taken together with the carbon atom to which they are attached form a cyclopropyl ring or an oxetanyl ring;

R⁸ is H, Me, F, CH₂F, CHF₂, CF₃, CN, CH₂CN, CH₂OMe, CH₂OH, C(O)OH, C(O)OMe or SO₂Me;

Linker is an optionally substituted linking moiety comprising a branched or unbranched, cyclized or uncyclized, saturated or unsaturated chain of 6 to 15 carbon atoms in length, wherein 1 to 6 of the carbon atoms are optionally replaced with a heteroatom independently selected from O, N and S.

2. The compound of Formula (I), or a pharmaceutically acceptable salt thereof, as claimed in claim 1, wherein the Linker is a C₃₋₁₄ alkylene chain wherein one to four -CH₂- units in the alkylene chain may independently optionally be replaced with a group selected from -O-, -NH-, -NMe-, cycloalkyl, heterocycloalkyl, aryl and heteroaryl.

3. The compound of Formula (I), or a pharmaceutically acceptable salt thereof, as claimed in any preceding claim, wherein the Linker is a C₃₋₁₄ alkylene chain wherein one to four -CH₂- units in the alkylene chain are optionally replaced with a group independently selected from -O-, -NMe-, cycloalkyl and heterocycloalkyl.

5 4. The compound of Formula (I), or a pharmaceutically acceptable salt thereof, as claimed in any preceding claim, wherein Linker is represented by the moiety -X-[W]_p-Het¹-, wherein:

X is selected from the group consisting of -Het²-C₁₋₆alkylene-, -C(O)-Het²-C₁₋₆alkylene-, -Het²-C(O)-C₁₋₆alkylene-, -C₁₋₆alkenylene-, -O-Het²-C₁₋₆alkylene-, -C₁₋₆alkylene- and -O-Cyc-C₁₋₆alkylene, wherein one or two -CH₂- units in the alkylene chain is independently replaced with -O-, -NH- or -NMe-;

10 W is selected from -Het³-C₁₋₆ alkylene-;

Het¹ is a nitrogen containing monocyclic or bicyclic heterocycloalkyl group;

Het² is a nitrogen containing monocyclic or bicyclic heterocycloalkyl group;

Het³ is a nitrogen containing monocyclic or bicyclic heterocycloalkyl group;

Cyc is C₃₋₆cycloalkyl;

15 p is 0 or 1;

wherein heterocycloalkyl is optionally substituted with 1 or 2 oxo substituents.


5. The compound of Formula (I), or a pharmaceutically acceptable salt thereof, as claimed in claim 4, wherein Het¹ is selected from the group consisting of piperidin-1-yl, piperazin-1-yl, 3,9-diazaspiro[5.5]undecan-3-yl, 7-oxa-3,10-diazaspiro[5.6]dodecan-3-yl, 3-oxopiperazin-1-yl, 2,7-diazaspiro[3.5]nonan-7-yl, 2,6-diazaspiro[3.3]heptan-2-yl, azetidin-1-yl and 2,5-diazabicyclo[2.2.1]heptan-2-yl.


6. The compound of Formula (I), or a pharmaceutically acceptable salt thereof, as claimed in claim 4 or claim 5, wherein Het² is selected from the group consisting of piperidin-4-yl, 3,9-diazaspiro[5.5]undecan-3-yl, 7-oxa-3,10-diazaspiro[5.6]dodecan-10-yl, 7-azaspiro[3.5]nonan-2-yl, 2-oxo-3,9-diazaspiro[5.5]undecan-3-yl, 2,7-diazaspiro[3.5]nonan-2-yl, 6-azaspiro[2.5]octan-1-yl, azetidin-3-yl and 3-azaspiro[5.5]undecan-3-yl.

7. The compound of Formula (I), or a pharmaceutically acceptable salt thereof, as claimed in any one of claims 4 to 6, wherein Het³ is selected from the group consisting of piperidin-4-yl, piperazin-1-yl and azetidin-1-yl.


8. The compound of Formula (I), or a pharmaceutically acceptable salt thereof, as claimed in any one of claims 4 to 7, wherein Cyc is cyclobutyl.

9. The compound of Formula (I), or a pharmaceutically acceptable salt thereof, as claimed in any preceding claim, wherein Linker is selected from the group consisting of:







10. The compound of Formula (I), or a pharmaceutically acceptable salt thereof, as claimed in any preceding claim, wherein the moiety:




is selected from the group consisting of




11. The compound of Formula (I), or a pharmaceutically acceptable salt thereof, as claimed in any preceding claim, wherein the moiety:




is selected from the group consisting of



12. The compound of Formula (I), or a pharmaceutically acceptable salt thereof, as claimed in any preceding claim, wherein the group $-\text{CH}_2-\text{C}(\text{R}^6)(\text{R}^7)(\text{R}^8)$ is selected from the group consisting of:



13. The compound of Formula (I), or a pharmaceutically acceptable salt thereof, as claimed in any preceding claim, wherein the group $-\text{CH}_2-\text{C}(\text{R}^6)(\text{R}^7)(\text{R}^8)$ is selected from the group consisting of:



14. The compound of Formula (I), or a pharmaceutically acceptable salt thereof, as claimed in any preceding claim, wherein R^3 and R^4 are both H or one of R^3 or R^4 is OMe and the other is H.

15. The compound of Formula (I), or a pharmaceutically acceptable salt thereof, as claimed in any preceding claim, wherein R^1 and R^2 are both H.

16. The compound of Formula (I), or a pharmaceutically acceptable salt thereof, as claimed in claim 1, wherein the compound is selected from the group consisting of:

3-[5-[4-[1-[5-[(1R,3R)-2-(2-Fluoro-2-methyl-propyl)-3-methyl-1,3,4,9-tetrahydropyrido[3,4-b]indol-1-yl]pyrimidin-2-yl]-4-piperidyl]methyl]piperazin-1-yl]-1-oxo-isoindolin-2-yl]piperidine-2,6-dione;

3-[5-[4-[2-[1-[5-[(1R,3R)-2-(2-Fluoro-2-methyl-propyl)-3-methyl-1,3,4,9-tetrahydropyrido[3,4-b]indol-1-yl]pyrimidin-2-yl]-4-piperidyl]ethyl]piperazin-1-yl]-1-oxo-isoindolin-2-yl]piperidine-2,6-dione;

2-[2,6-Dioxo-3-piperidyl]-5-[4-[1-[5-[(1R,3R)-2-(2-fluoro-2-methyl-propyl)-3-methyl-1,3,4,9-tetrahydropyrido[3,4-b]indol-1-yl]pyrimidin-2-yl]-4-piperidyl]methyl]piperazin-1-yl]isoindoline-1,3-dione formate;

3-[5-[4-[2-[1-[5-[(1R,3R)-2-(2-Fluoro-2-methyl-propyl)-3-methyl-1,3,4,9-tetrahydropyrido[3,4-b]indol-1-yl]pyrimidin-2-yl]-4-piperidyl]oxy]ethyl]piperazin-1-yl]-1-oxo-isoindolin-2-yl]piperidine-2,6-dione;

3-[5-[4-[5-[3,5-Difluoro-4-[(1*R*,3*R*)-2-(2-fluoro-2-methyl-propyl)-3-methyl-1,3,4,9-tetrahydropyrido[3,4-b]indol-1-yl]phenoxy]pentyl]piperazin-1-yl]-1-oxo-isoindolin-2-yl]piperidine-2,6-dione;

3-{5-[4-({4-[(1-{5-[(1*R*,3*R*)-2-(2-fluoro-2-methylpropyl)-3-methyl-2,3,4,9-tetrahydro-1*H*-beta-carbolin-1-yl]pyrimidin-2-yl}piperidin-4-yl)methyl]piperazin-1-yl)methyl}piperidin-1-yl]-1-oxo-1,3-dihydro-2*H*-isoindol-2-yl}piperidine-2,6-dione;

3-(5-{9-[(1-{5-[(1*R*,3*R*)-2-(2-fluoro-2-methylpropyl)-3-methyl-2,3,4,9-tetrahydro-1*H*-beta-carbolin-1-yl]pyrimidin-2-yl}piperidin-4-yl)methyl]-3,9-diazaspiro[5.5]undecan-3-yl]-1-oxo-1,3-dihydro-2*H*-isoindol-2-yl}piperidine-2,6-dione;

3-(5-{4-[3-(1-{5-[(1*R*,3*R*)-2-(2-fluoro-2-methylpropyl)-3-methyl-2,3,4,9-tetrahydro-1*H*-beta-carbolin-1-yl]pyrimidin-2-yl}piperidin-4-yl)propyl]piperazin-1-yl]-1-oxo-1,3-dihydro-2*H*-isoindol-2-yl}piperidine-2,6-dione;

3-(5-{4-[(9-{5-[(1*R*,3*R*)-2-(2-fluoro-2-methylpropyl)-3-methyl-2,3,4,9-tetrahydro-1*H*-beta-carbolin-1-yl]pyrimidin-2-yl}-3,9-diazaspiro[5.5]undecan-3-yl)methyl]piperidin-1-yl]-1-oxo-1,3-dihydro-2*H*-isoindol-2-yl}piperidine-2,6-dione;

3-(5-{4-[2-(9-{5-[(1*R*,3*R*)-2-(2-fluoro-2-methylpropyl)-3-methyl-2,3,4,9-tetrahydro-1*H*-beta-carbolin-1-yl]pyrimidin-2-yl}-3,9-diazaspiro[5.5]undecan-3-yl)ethyl]piperidin-1-yl]-1-oxo-1,3-dihydro-2*H*-isoindol-2-yl}piperidine-2,6-dione;

3-(5-{9-[2-(1-{5-[(1*R*,3*R*)-2-(2-fluoro-2-methylpropyl)-3-methyl-2,3,4,9-tetrahydro-1*H*-beta-carbolin-1-yl]pyrimidin-2-yl}piperidin-4-yl)ethyl]-3,9-diazaspiro[5.5]undecan-3-yl]-1-oxo-1,3-dihydro-2*H*-isoindol-2-yl}piperidine-2,6-dione;

3-(5-{4-[2-(1-{5-[(1*R*,3*R*)-2-(2-fluoro-2-methylpropyl)-3-methyl-2,3,4,9-tetrahydro-1*H*-beta-carbolin-1-yl]pyrimidin-2-yl}piperidin-4-yl)ethyl]piperazin-1-yl]-7-methoxy-1-oxo-1,3-dihydro-2*H*-isoindol-2-yl}piperidine-2,6-dione;

3-(5-{4-[3-(1-{5-[(1*R*,3*R*)-2-(2-fluoro-2-methylpropyl)-3-methyl-2,3,4,9-tetrahydro-1*H*-beta-carbolin-1-yl]pyrimidin-2-yl}piperidin-4-yl)propyl]piperazin-1-yl]-7-methoxy-1-oxo-1,3-dihydro-2*H*-isoindol-2-yl}piperidine-2,6-dione;

3-{5-[4-({1-[(1-{5-[(1*R*,3*R*)-2-(2-fluoro-2-methylpropyl)-3-methyl-2,3,4,9-tetrahydro-1*H*-beta-carbolin-1-yl]pyrimidin-2-yl}piperidin-4-yl)methyl]piperidin-4-yl)methyl}piperazin-1-yl]-1-oxo-1,3-dihydro-2*H*-isoindol-2-yl}piperidine-2,6-dione;

3-(5-{4-[2-(1-{5-[(1*R*,3*R*)-3-methyl-2-(2,2,2-trifluoroethyl)-2,3,4,9-tetrahydro-1*H*-beta-carbolin-1-yl]pyrimidin-2-yl}piperidin-4-yl)ethyl]piperazin-1-yl]-1-oxo-1,3-dihydro-2*H*-isoindol-2-yl}piperidine-2,6-dione;

3-(5-{4-[(3-[(1-{5-[(1*R*,3*R*)-2-(2-fluoro-2-methylpropyl)-3-methyl-2,3,4,9-tetrahydro-1*H*-beta-carbolin-1-yl]pyrimidin-2-yl}piperidin-4-yl)methyl](methyl)amino}azetidin-1-yl)methyl]piperidin-1-yl]-1-oxo-1,3-dihydro-2*H*-isoindol-2-yl}piperidine-2,6-dione;

3-(5-{4-[2-(3-{5-[(1R,3R)-2-(2-fluoro-2-methylpropyl)-3-methyl-2,3,4,9-tetrahydro-1H-beta-carbolin-1-yl]pyrimidin-2-yl}-7-oxa-3,10-diazaspiro[5.6]dodecan-10-yl)ethyl]piperidin-1-yl}-1-oxo-1,3-dihydro-2H-isoindol-2-yl)piperidine-2,6-dione;

3-(5-{4-[(3-{5-[(1R,3R)-2-(2-fluoro-2-methylpropyl)-3-methyl-2,3,4,9-tetrahydro-1H-beta-carbolin-1-yl]pyrimidin-2-yl}-7-oxa-3,10-diazaspiro[5.6]dodecan-10-yl)methyl]piperidin-1-yl}-1-oxo-1,3-dihydro-2H-isoindol-2-yl)piperidine-2,6-dione;

3-(5-{10-[(1-{5-[(1R,3R)-2-(2-fluoro-2-methylpropyl)-3-methyl-2,3,4,9-tetrahydro-1H-beta-carbolin-1-yl]pyrimidin-2-yl]piperidin-4-yl)methyl]-7-oxa-3,10-diazaspiro[5.6]dodecan-3-yl}-1-oxo-1,3-dihydro-2H-isoindol-2-yl)piperidine-2,6-dione;

3-(5-{10-[2-(1-{5-[(1R,3R)-2-(2-fluoro-2-methylpropyl)-3-methyl-2,3,4,9-tetrahydro-1H-beta-carbolin-1-yl]pyrimidin-2-yl]piperidin-4-yl)ethyl]-7-oxa-3,10-diazaspiro[5.6]dodecan-3-yl}-1-oxo-1,3-dihydro-2H-isoindol-2-yl)piperidine-2,6-dione;

3-(5-{9-[(1-{6-[(1S,3R)-2-(2-fluoro-2-methylpropyl)-3-methyl-2,3,4,9-tetrahydro-1H-beta-carbolin-1-yl]pyridin-3-yl]piperidin-4-yl)methyl]-3,9-diazaspiro[5.5]undecan-3-yl}-1-oxo-1,3-dihydro-2H-isoindol-2-yl)piperidine-2,6-dione;

3-(5-{9-[(7-{5-[(1R,3R)-2-(2-fluoro-2-methylpropyl)-3-methyl-2,3,4,9-tetrahydro-1H-beta-carbolin-1-yl]pyrimidin-2-yl}-7-azaspiro[3.5]nonan-2-yl)methyl]-3,9-diazaspiro[5.5]undecan-3-yl}-1-oxo-1,3-dihydro-2H-isoindol-2-yl)piperidine-2,6-dione;

3-[5-(9-{2-[(1S,3r)-3-({5-[(1R,3R)-2-(2-fluoro-2-methylpropyl)-3-methyl-2,3,4,9-tetrahydro-1H-beta-carbolin-1-yl]pyrimidin-2-yl}oxy)cyclobutyl]ethyl)-3,9-diazaspiro[5.5]undecan-3-yl}-1-oxo-1,3-dihydro-2H-isoindol-2-yl)piperidine-2,6-dione;

3-(5-{9-[5-({5-[(1R,3R)-2-(2-fluoro-2-methylpropyl)-3-methyl-2,3,4,9-tetrahydro-1H-beta-carbolin-1-yl]pyrimidin-2-yl}oxy)pentyl]-3,9-diazaspiro[5.5]undecan-3-yl}-1-oxo-1,3-dihydro-2H-isoindol-2-yl)piperidine-2,6-dione;

3-(5-{4-[2-(9-{5-[(1R,3R)-2-(2-fluoro-2-methylpropyl)-3-methyl-2,3,4,9-tetrahydro-1H-beta-carbolin-1-yl]pyrimidin-2-yl}-2-oxo-3,9-diazaspiro[5.5]undecan-3-yl)ethyl]piperazin-1-yl}-1-oxo-1,3-dihydro-2H-isoindol-2-yl)piperidine-2,6-dione;

3-(5-{4-[2-(9-{5-[(1R,3R)-2-(2-fluoro-2-methylpropyl)-3-methyl-2,3,4,9-tetrahydro-1H-beta-carbolin-1-yl]pyrimidin-2-yl}-3,9-diazaspiro[5.5]undecan-3-yl)ethyl]-3-oxopiperazin-1-yl}-1-oxo-1,3-dihydro-2H-isoindol-2-yl)piperidine-2,6-dione;

3-(5-{4-[(7-{5-[(1R,3R)-2-(2-fluoro-2-methylpropyl)-3-methyl-2,3,4,9-tetrahydro-1H-beta-carbolin-1-yl]pyrimidin-2-yl}-7-azaspiro[3.5]nonan-2-yl)methyl]piperazin-1-yl}-1-oxo-1,3-dihydro-2H-isoindol-2-yl)piperidine-2,6-dione;

3-(5-{2-[(7-{5-[(1R,3R)-2-(2-fluoro-2-methylpropyl)-3-methyl-2,3,4,9-tetrahydro-1H-beta-carbolin-1-yl]pyrimidin-2-yl}-7-azaspiro[3.5]nonan-2-yl)methyl]-2,7-diazaspiro[3.5]nonan-7-yl}-1-oxo-1,3-dihydro-2H-isoindol-2-yl)piperidine-2,6-dione;

3-(5-{4-[(7-{5-[(1R,3R)-2-(2-fluoro-2-methylpropyl)-3-methyl-2,3,4,9-tetrahydro-1H-beta-carbolin-1-yl]pyrimidin-2-yl}-2,7-diazaspiro[3.5]nonan-2-yl)methyl]piperidin-1-yl}-1-oxo-1,3-dihydro-2H-isoindol-2-yl)piperidine-2,6-dione;

3-(5-{6-[(1-{5-[(1R,3R)-2-(2-fluoro-2-methylpropyl)-3-methyl-2,3,4,9-tetrahydro-1H-beta-carbolin-1-yl]pyrimidin-2-yl}piperidin-4-yl)methyl]-2,6-diazaspiro[3.3]heptan-2-yl}-1-oxo-1,3-dihydro-2H-isoindol-2-yl)piperidine-2,6-dione;

3-(5-{4-[(6-{5-[(1R,3R)-2-(2-fluoro-2-methylpropyl)-3-methyl-2,3,4,9-tetrahydro-1H-beta-carbolin-1-yl]pyrimidin-2-yl}-6-azaspiro[2.5]octan-1-yl)methyl]piperazin-1-yl}-1-oxo-1,3-dihydro-2H-isoindol-2-yl)piperidine-2,6-dione;

3-[5-(3-{[2-(1-{5-[(1R,3R)-2-(2-fluoro-2-methylpropyl)-3-methyl-2,3,4,9-tetrahydro-1H-beta-carbolin-1-yl]pyrimidin-2-yl}piperidin-4-yl)ethyl](methyl)amino}azetidin-1-yl)-1-oxo-1,3-dihydro-2H-isoindol-2-yl)piperidine-2,6-dione;

3-(5-{(1R,4R)-5-[3-(1-{5-[(1R,3R)-2-(2-fluoro-2-methylpropyl)-3-methyl-2,3,4,9-tetrahydro-1H-beta-carbolin-1-yl]pyrimidin-2-yl}piperidin-4-yl)propyl]-2,5-diazabicyclo[2.2.1]heptan-2-yl}-1-oxo-1,3-dihydro-2H-isoindol-2-yl)piperidine-2,6-dione;

3-(5-{4-[3-(1-{5-[(1R,3R)-3-methyl-2-(2,2,2-trifluoroethyl)-2,3,4,9-tetrahydro-1H-beta-carbolin-1-yl]pyrimidin-2-yl}piperidin-4-yl)propyl]piperazin-1-yl}-1-oxo-1,3-dihydro-2H-isoindol-2-yl)piperidine-2,6-dione;

3-(5-{4-[(1-{5-[(1R,3R)-3-methyl-2-(2,2,2-trifluoroethyl)-2,3,4,9-tetrahydro-1H-beta-carbolin-1-yl]pyrimidin-2-yl}piperidin-4-yl)methyl]piperazin-1-yl}-1-oxo-1,3-dihydro-2H-isoindol-2-yl)piperidine-2,6-dione;

3-(5-{4-[1-(1-{5-[(1R,3R)-2-(2-fluoro-2-methylpropyl)-3-methyl-2,3,4,9-tetrahydro-1H-beta-carbolin-1-yl]pyrimidin-2-yl}piperidin-4-yl)ethyl]piperazin-1-yl}-1-oxo-1,3-dihydro-2H-isoindol-2-yl)piperidine-2,6-dione;

3-(5-{4-[2-(1-{5-[(1R,3R)-2-(2-fluoro-2-methylpropyl)-3-methyl-2,3,4,9-tetrahydro-1H-beta-carbolin-1-yl]pyrimidin-2-yl}azetidin-3-yl)ethyl]piperazin-1-yl}-1-oxo-1,3-dihydro-2H-isoindol-2-yl)piperidine-2,6-dione;

3-[5-(4-{3-[(1-{5-[(1R,3R)-2-(2-fluoro-2-methylpropyl)-3-methyl-2,3,4,9-tetrahydro-1H-beta-carbolin-1-yl]pyrimidin-2-yl}piperidin-4-yl)oxy]propyl}piperazin-1-yl)-1-oxo-1,3-dihydro-2H-isoindol-2-yl)piperidine-2,6-dione;

3-(5-{4-[(1-{5-[(1R,3R)-2-(2-fluoro-2-methylpropyl)-3-methyl-2,3,4,9-tetrahydro-1H-beta-carbolin-1-yl]pyrimidin-2-yl}piperidin-4-yl)methyl]piperazin-1-yl}-7-methoxy-1-oxo-1,3-dihydro-2H-isoindol-2-yl)piperidine-2,6-dione;

3-(5-{4-[5-({5-[(1R,3R)-2-(2-fluoro-2-methylpropyl)-3-methyl-2,3,4,9-tetrahydro-1H-beta-carbolin-1-yl]pyrimidin-2-yl}oxy)pentyl]piperazin-1-yl}-1-oxo-1,3-dihydro-2H-isoindol-2-yl)piperidine-2,6-dione; and
 3-[5-(4-{[9-({5-[(1R,3R)-2-(2-fluoro-2-methylpropyl)-3-methyl-2,3,4,9-tetrahydro-1H-beta-carbolin-1-yl]pyrimidin-2-yl}oxy)-3-azaspiro[5.5]undecan-3-yl)methyl}piperidin-1-yl)-1-oxo-1,3-dihydro-2H-isoindol-2-yl]piperidine-2,6-dione.

17. A pharmaceutical composition comprising a compound of Formula (I), or a pharmaceutically acceptable salt thereof, as claimed in any preceding claim, and at least one pharmaceutically acceptable excipient.

18. A compound of Formula (I), or a pharmaceutically acceptable salt thereof, as claimed in any one of claims 1 to 16, for use in therapy.

19. A compound of Formula (I), or a pharmaceutically acceptable salt thereof, as claimed in any one of claims 1 to 16, for use in the treatment of cancer.

20. Use of a compound of Formula (I), or a pharmaceutically acceptable salt thereof, as claimed in any one of claims 1 to 16, for the manufacture of a medicament for the treatment of cancer.

21. Use of a compound of Formula (I), or a pharmaceutically acceptable salt thereof, as claimed in any one of claims 1 to 16 for the manufacture of a medicament for the treatment of cancer in a warm-blooded animal in need of such treatment, wherein a therapeutically effective amount of the compound of Formula (I) or a pharmaceutically acceptable salt thereof is to be administered to said warm-blooded animal.

22. The compound for use, or use as claimed in any one of claims 19 to 21, wherein the cancer is selected from breast, endometrium, ovary and cervix.